Ge Long Hui·2025-10-24 09:27Core Insights - China Resources Pharmaceutical (03320.HK) reported that Tianjin Tasly Pharmaceutical achieved total revenue of RMB 6.311 billion for the nine months ending September 30, 2025, a year-on-year decrease of 2.35% [1] - The net profit for Tianjin Tasly Pharmaceutical was RMB 999 million, reflecting a year-on-year increase of 19.85% [1] - As of the end of the reporting period, the cash and cash equivalents balance stood at RMB 1.183 billion [1] Group 1 - Tianjin Tasly Pharmaceutical's total revenue decreased by 2.35% year-on-year to RMB 6.311 billion [1] - The net profit increased by 19.85% year-on-year to RMB 999 million [1] - The cash and cash equivalents at the end of the period were RMB 1.183 billion [1] Group 2 - China Resources Pharmaceutical holds approximately 28% equity in Tianjin Tasly Pharmaceutical through its non-wholly owned subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. [1] - The shares of Tianjin Tasly Pharmaceutical are listed on the Shanghai Stock Exchange [1]